The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
1
Edited News | OHCHR , UNOG
The telecommunications shutdowns in Afghanistan in September had serious and far-reaching impacts on people’s lives, according to a briefing paper published today by the UN Human Rights Office and the UN Assistance Mission in Afghanistan (UNAMA).
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Office spokesperson Jeremy Laurence at the UN Geneva press briefing made the following comment on the ASEAN declaration on the right to a healthy environment.
1
1
1
Edited News | IFRC , OCHA , WMO
‘Catastrophic’ Hurricane Melissa hours from landfall in Jamaica as humanitarians rush to save lives
Millions in Jamaica and across the Caribbean are bracing for massive impact from Hurricane Melissa on Tuesday as the UN and partners are warning of a “severe” and “immediate” humanitarian threat.
1
1
Edited News | WHO
‘We need all routes to open’: in Gaza WHO calls for ramp-up of medevacs, easier access for essentials
Two weeks since a ceasefire agreement entered into force in Gaza the World Health Organization (WHO) noted progress on the flow of aid while calling for more evacuations of critical patients and eased entry for essential medicines and supplies.
1
12
1
1
Edited News | WMO , UNITED NATIONS
UN chief urges boost to life-saving weather warning systems, stresses role of climate change science
No country is safe from the devastating impacts of extreme weather — and saving lives means making early-warning systems accessible to all, UN chief António Guterres said on Wednesday.
1
1
1
Edited News | WFP
Gazans’ response to food distributions ‘overwhelming’ as humanitarians scale up under fragile ceasefire
In Gaza, the ceasefire is enabling UN humanitarians to reach more desperate people with life-saving food, but greater access is needed to contain the spread of famine.
1
1
1
Edited News | WFP , OCHA
UN urges opening of all Gaza crossings to deliver three-month food supply
The UN World Food Programme (WFP) has warned food aid cannot reach everyone in Gaza unless all border crossings are opened, particularly in the north where famine was declared in August. The agency says it already has enough supplies in place to feed the entire population of the Strip for three months – if full access is granted by Israel.
1
1
1
Edited News | UNDP , UNICEF , OCHA , ICRC
Around $70 billion will be needed to reconstruct Gaza and make it safe after two years of war, UN development experts said on Tuesday, while aid agencies reported that far too little aid continues to reach desperate Palestinians.
1
1
1
Edited News | OHCHR
The UN human rights office, OHCHR, on Friday welcomed the Nobel Peace Prize committee’s decision to name Maria Machado as this year’s laureate, in recognition of her work promoting the Venezuelan people’s democratic hopes.
1
1
1
Edited News | UNRWA , UNICEF , WHO
As Gazans jammed the main route leading north on Friday after a ceasefire deal between Israel and Hamas was announced, UN aid teams repeated their call to open all crossings into the devastated enclave to prevent famine spreading.
1
1
1
Edited News | OCHA , UNICEF , WHO
Two years of Gaza-Israel war bring ‘indescribable’ pain: UN humanitarians
Two years since the Hamas-led terror attacks on Israel, UN humanitarians on Tuesday reiterated calls for the release of all hostages in Gaza, an immediate ceasefire and an aid surge to alleviate Palestinians’ suffering, as talks on a US-driven peace plan continued in Egypt.
1
1
1
Edited News
Syria prison survivor seeks justice for the missing with UN backing.